Skip to main content
Erschienen in: Neurotherapeutics 2/2015

01.04.2015 | Editorial

The Spectrum of Motor Neuron Diseases: From Childhood Spinal Muscular Atrophy to Adult Amyotrophic Lateral Sclerosis

verfasst von: Stacey A. Sakowski, Eva L. Feldman

Erschienen in: Neurotherapeutics | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Excerpt

Since the topic of motor neuron diseases was last covered in Neurotherapeutics in 2008, increasing insight into genetic causes and underlying disease mechanisms has fueled several advances that have paved the way for new therapeutic strategies that are currently in development or being tested in clinical trials. In this special issue, we present reviews by leading investigators in the field that detail these advances for spinal muscular atrophy (SMA), an inherited neuromuscular disease associated with motor neuron degeneration and muscle atrophy that presents early in life, and amyotrophic lateral sclerosis (ALS), a fatal adult-onset neuromuscular disease also characterized by loss of motor neurons. The papers are divided into 4 main sections that cover 1) SMA advances, 2) ALS challenges and recent biological advances, 3) ALS clinical trial design considerations and outcome measures, and 4) emerging ALS treatments. Together, these articles offer a timely and comprehensive look into the recent research advances, current clinical considerations, and therapeutic prospects currently in development or being tested for motor neuron diseases. …
Literatur
3.
Zurück zum Zitat Rosenfeld J, Strong M. Challenges in the understanding and treatment of amyotrophic lateral sclerosis/motor neuron disease. Neurother 2015. doi:10.1007/s13311-014-0332-8 (in this issue). Rosenfeld J, Strong M. Challenges in the understanding and treatment of amyotrophic lateral sclerosis/motor neuron disease. Neurother 2015. doi:10.​1007/​s13311-014-0332-8 (in this issue).
4.
Zurück zum Zitat Cooper-Knock J, Kirby J, Highley R, Shaw PJ. The spectrum of C9orf72-mediated neurodegeneration and amyotrophic lateral sclerosis. Neurother 2015. doi:10.1007/s13311-015-0342-1 (in this issue). Cooper-Knock J, Kirby J, Highley R, Shaw PJ. The spectrum of C9orf72-mediated neurodegeneration and amyotrophic lateral sclerosis. Neurother 2015. doi:10.​1007/​s13311-015-0342-1 (in this issue).
6.
Zurück zum Zitat Scotter E, Chen H-J, Shaw C. TDP-43 proteinopathy and ALS: Insights into disease mechanism and therapeutic targets. Neurother 2015. doi:10.1007/s13311-015-0338-x (in this issue). Scotter E, Chen H-J, Shaw C. TDP-43 proteinopathy and ALS: Insights into disease mechanism and therapeutic targets. Neurother 2015. doi:10.​1007/​s13311-015-0338-x (in this issue).
7.
8.
Zurück zum Zitat Nicholson K, Cudkowicz M, Berry J. Clinical trial designs in amyotrophic lateral sclerosis: Does one design fit all? Neurother 2015. doi:10.1007/s13311-015-0341-2 (in this issue). Nicholson K, Cudkowicz M, Berry J. Clinical trial designs in amyotrophic lateral sclerosis: Does one design fit all? Neurother 2015. doi:10.​1007/​s13311-015-0341-2 (in this issue).
11.
12.
14.
Zurück zum Zitat Goutman SA, Chen KS, Feldman EL. Recent advances and the future of stem cell therapies in amyotrophic lateral sclerosis. Neurother 2015. doi:10.1007/s13311-015-0339-9 (in this issue). Goutman SA, Chen KS, Feldman EL. Recent advances and the future of stem cell therapies in amyotrophic lateral sclerosis. Neurother 2015. doi:10.​1007/​s13311-015-0339-9 (in this issue).
Metadaten
Titel
The Spectrum of Motor Neuron Diseases: From Childhood Spinal Muscular Atrophy to Adult Amyotrophic Lateral Sclerosis
verfasst von
Stacey A. Sakowski
Eva L. Feldman
Publikationsdatum
01.04.2015
Verlag
Springer US
Erschienen in
Neurotherapeutics / Ausgabe 2/2015
Print ISSN: 1933-7213
Elektronische ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-015-0349-7

Weitere Artikel der Ausgabe 2/2015

Neurotherapeutics 2/2015 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.